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Background
The objective of this randomised controlled trial (RCT)
was to comparatively assess the effectiveness of intra-
articular hyaluronan (Synvisc
®, hylan G-F 20) against an
intra-articular sterile saline placebo for the treatment of
radiographically confirmed, symptomatic first metatarso-
phalangeal joint (MTPJ) osteoarthritis (OA).
Methods
One hundred and fifty one (n=151) participants with symp-
tomatic first MTPJ OA were randomly allocated to receive
up to 1ml intra-articular injection of either Synvisc
®,h y l a n
G-F 20 or a sterile saline placebo. Outcomes were evalu-
ated at 1, 3 and 6 months post-injection. Primary outcome
measurements included the foot pain and foot function
sub-scales of the Foot Health Status Questionnaire
(FHSQ). Secondary outcome measurements were pain at
the first MTPJ during walking and rest, self-reported stiff-
ness at the first MTPJ, magnitude of symptom change with
allocated treatment, global satisfaction, health-related qual-
ity of life (assessed via the Short-Form-36, version two),
first MTPJ dorsiflexion range of motion, strength of the
hallux plantarflexors, use of pain-relieving medication, con-
comitant therapies and dynamic plantar pressures.
Results
This RCT was completed in July 2010, with 147 (97%)
participants followed up at 1 month, 127 (84%) at
3 months and 135 (89%) at 6 months. Both the placebo
and treatment groups displayed improvements at the 1,
3, and 6 month follow-up periods. However, there were
no statistically significant differences between the
placebo or treatment groups for the primary outcome
measures of FHSQ foot pain and footfunction during any
review period. With few exceptions, there were no
statistically significant differences in the secondary
outcome measurements between the groups.
Conclusions
A single intra-articular injection of Synvisc
®, hylan G-F
20 is no more effective than a single intra-articular
injection of sterile saline (placebo) in reducing symp-
toms and improving function in people with sympto-
matic, radiographically confirmed first MTPJ OA.
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